Evogene Ltd. filings document a foreign private issuer whose disclosures are centered on computational chemistry, ChemPass AI™, and small-molecule product development for pharmaceutical and agricultural markets. Form 6-K reports furnish quarterly and annual financial results, unaudited consolidated financial statements, operating and financial review materials, and presentations incorporated by reference into registration statements.
The filing record also covers material agreements and corporate events tied to Evogene's subsidiaries and platform strategy, including Biomica's BMC128 licensing disclosure, management changes, Nasdaq minimum-bid-price correspondence, and capital-structure disclosures through Form F-3 and Form S-8 references. These documents describe governance and financing context for EVGN ordinary shares and the company's operating subsidiaries.
Evogene Ltd. (EVGN) granted director Leon Recanati 2,500 stock options on September 4, 2026, with an exercise price of $0.58 per ordinary share. The options were granted under Evogene's 2021 Share Incentive Plan and vest quarterly at 25% per quarter beginning September 4, 2026, becoming fully vested September 4, 2027. They expire September 4, 2036. A separate informational holding entry lists 1,343,886 ordinary shares held directly.
Evogene Ltd. director Nir Nimrodi received 10,000 stock options on September 4, 2026, under the company’s 2021 Share Incentive Plan. The options have an exercise price of NIS 1.75 per share, equivalent to $0.58 per share, vest 25% per quarter beginning on the grant date, become fully vested by September 4, 2027, and expire September 4, 2036.
The filing also lists existing direct options covering 5,625 ordinary shares at an $11.00 exercise price, expiring April 20, 2030; 1,800 shares each at $10.20, $6.40 and $6.60, expiring September 15, 2032, May 11, 2033 and June 15, 2034; and 10,000 shares at $1.29, expiring August 18, 2035.
Evogene Ltd. (EVGN) director Adrian John Percy received a grant of 2,500 stock options on September 4, 2026, under the 2021 Share Incentive Plan. The options have a $0.58-per-share exercise price and vest 25% per quarter beginning on the grant date, becoming fully vested by September 4, 2027; they expire September 4, 2036. Separately, reported direct options include 1,000 underlying shares at $25.60, expiring December 23, 2028, and 2,500 at $1.29, expiring August 18, 2035.
Evogene Ltd. reported that director Dan Michael Falk received a grant of 2,500 stock options on September 4, 2026, under the company's 2021 Share Incentive Plan. The options cover 2,500 ordinary shares and have an exercise price of $0.58 per share.
The options vest quarterly at 25% per quarter beginning September 4, 2026, and become fully vested by September 4, 2027. The report also lists four direct option holdings: 1,800 underlying shares at $10.51, expiring September 15, 2032; 1,800 at $6.03, expiring May 11, 2033; 1,800 at $7.16, expiring June 13, 2034; and 2,500 at $1.29, expiring August 18, 2035.
Evogene Ltd. (EVGN) received a Nasdaq letter granting an additional 180 calendar days, through March 29, 2027, to regain compliance with the minimum bid-price requirement. Compliance requires a closing bid price of at least $1.00 per share for a minimum of ten consecutive business days during the period.
The letter has no immediate effect on Evogene’s Nasdaq listing or trading. If Evogene does not demonstrate compliance with the bid-price or other listing requirements by March 29, 2027, Nasdaq staff will provide written notification that its securities will be delisted. If the issue remains unresolved, Evogene intends to consider other options, potentially including a reverse share split.
Evogene Ltd. reported $681,000 in revenue for the six months ended June 30, 2026, compared with $2.877 million a year earlier; gross profit was $345,000 versus $1.224 million. Operating loss was $5.387 million versus $4.853 million, while net loss was $7.663 million versus $7.671 million. Lower revenue primarily reflected lower Casterra seed sales, following approximately $2.0 million in seed sales in the first half of 2025.
Net cash used in operating activities was $4.928 million, versus $7.483 million; cash and cash equivalents were $9.316 million as of June 30, 2026. Management believes available cash, including funds raised through August under the warrant inducement and AGP Sales Agreement, will be sufficient for projected cash requirements for at least the next 12 months. The AGP at-the-market offering’s maximum aggregate offering price rose to $3,288,113 on July 17; gross proceeds under the agreement were approximately $3.28 million as of August 31.
Evogene’s 2025 strategy shift focuses activities on ChemPass AI and small-molecule products for pharmaceutical and agricultural markets. Shareholders approved a reverse-split framework ranging from 1-for-2 to 1-for-15, with the board to determine the ratio and date within 18 months of September 4, 2026.
Evogene Ltd. (EVGN) is terminating a resale registration covering up to 3,384,616 ordinary shares after the selling shareholder sold all registered shares. The shares were issued to the selling shareholder after it exercised all 3,384,616 ordinary warrants on February 11, 2026, under an inducement offer letter agreement entered into with Evogene on February 10, 2026. Upon effectiveness, the registration statement, including its prospectuses and supplements, will be deregistered and terminated.
Evogene Ltd. (EVGN) reports that following its annual general meeting held on September 4, 2026, two dissident shareholders asserted claims concerning the published voting results and, on September 8, 2026, notified the company of their intention to initiate a special tender offer under Section 328 of the Israeli Companies Law, 5759-1999. The company states it is in discussions with these shareholders to resolve the matters. On September 9, 2026, directors Yoshinori Oikawa and Yael Margolin resigned from the board, and Evogene notes that their resignations were not related to any disagreement regarding its operations, policies or practices.
Evogene Ltd. (EVGN) received notice from a group of reporting persons, including L.I.A. Pure Capital Ltd., Invest Pro Shukai Hon Ltd., Kfir Silberman and Ron Yair Peled, that they intend to commence a special tender offer under Section 328 of the Israeli Companies Law.
The group currently reports beneficial ownership of 3,057,488 ordinary shares, representing 19.35% of Evogene’s ordinary shares, based on 15,801,407 shares outstanding as of July 27, 2026not less than 25% of Evogene’s outstanding voting rights.